At every stage of the product lifecycle, including research, pre-clinical, registration, clinical trials, processing, manufacturing equipment, instrument validation, quality maintenance, packaging, labeling, and more, pharmaceutical companies are subject to strict regulations and must maintain compliance with local governing bodies such as the FDA (Food & Drug Association), EMA (European Medical Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan), China's National Medical Products Administration (NMPA), CDSCO (Central Drugs Standard Control Organization, India), SFDA (Saudi Food and Drug Authority), and more. The pharmaceutical industry relies heavily on companies adhering to the regulations' lifespan, which is the basis for FDA approvals. Promoting and upholding the guarantee of drug use is the aim of the regulation. Throughout the drug life cycle, drug prices fluctuate and sharply decline following loss of exclusivity (LOE), and maybe earlier as a result of growing competition and probable price or volume agreements. Promoting and upholding the guarantee of drug use is the aim of the regulation. All stages of the drug's lifespan are logically defined by these regulations. These regulations coherently define the lifecycle of the drug at all phases. A novel drug's development is a multi-stage, time-consuming, and intricate procedure. It starts with the discovery phase, during which compounds with therapeutic promise are found and possible drug targets are identified. The next step is preclinical testing, which assesses these compounds' effectiveness and safety in both lab and animal experiments. In order to evaluate safety, efficacy, and dose, the medication undergoes phase I, II, and III clinical trials using human participants if it shows promise. Regulatory approval from organizations such as the FDA is sought following the successful conclusion of clinical trials. Following approval, the medication is put on the market and subjected to post-market surveillance to ensure its effectiveness and safety in actual use.[1]
It takes skill and diligence to navigate the regulatory environment of pharmaceutical product life cycle management. Businesses can improve compliance, reduce risks, and speed regulatory procedures by proactively addressing issues and enlisting outside help. External support provides crucial direction and experience at every level, from post-market surveillance to regulatory compliance and reporting. Businesses may successfully negotiate complexity and guarantee the success and integrity of their goods throughout their life cycle with the help of the appropriate partners and a clear regulatory plan. Adverse event reporting is a crucial component of post-market surveillance and pharmacovigilance since businesses are required to notify regulatory bodies of adverse occurrences. The FDA's MedWatch program requires that significant adverse events be reported within 15 days.The European Medicines Agency's EudraVigilance is a centralized database for reporting adverse events in Europe. While the FDA and EMA mandate the production of Periodic Safety Update Reports (PSURs) at predetermined intervals (often annually), PSURs are regular submissions of safety reports. The FDA and EMA require Risk Management Plans (RMPs) for new medications and major post-approval adjustments. RMPs are documents that describe the risk management system. [2]
From product development to post-market surveillance, quality risk management (QRM) is essential in identifying and reducing possible threats to the quality of the final product. The systematic process of identifying, evaluating, controlling, and reviewing threats to the quality of pharmaceutical goods across the course of their lifecycle is known as QRM. This covers phases such as post-market surveillance, manufacture, distribution, and development. Pharmaceutical firms use Good Manufacturing Practices (GMP), Quality Control (QC), and Quality Assurance (QA) to guarantee the quality of their products. To improve quality control, contemporary technol...
(All Rights Reserved)